SCHEMBL22637149

SCHEMBL22637149

Cc1oncc1-c1ccc(-c2ccccc2)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 8/20 0.51
MAPT P10636 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPK1 P28482 3/20 0.41
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD4 O60885 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
CASP1 P29466 1/20 0.36
NUDT1 P36639 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29430767 1.00 TDO2 (0.51) TDO2MAPTL3MBTL1MAPK1ALDH1A1
SCHEMBL29430584 0.86 TDO2 (0.56) TDO2MAPTALDH1A1PDE3BPDE3A
SCHEMBL29430620 0.86 MAPK1 (0.44) TDO2MAPTL3MBTL1MAPK1BRD4
SCHEMBL22636714 0.86 MAPK1 (0.44) TDO2MAPTL3MBTL1MAPK1BRD4
SCHEMBL22637054 0.86 TDO2 (0.56) TDO2MAPTALDH1A1PDE3BPDE3A
SCHEMBL7472158 0.83 TDO2 (0.59) TDO2MAPTL3MBTL1ALDH1A1HSD17B10
SCHEMBL22636845 0.82 TDO2 (0.55) TDO2MAPTL3MBTL1MAPK1ALDH1A1
SCHEMBL22636874 0.79 TDO2 (0.55) TDO2MAPTL3MBTL1MAPK1ALDH1A1
SCHEMBL29430744 0.79 TDO2 (0.55) TDO2MAPTL3MBTL1MAPK1ALDH1A1
SCHEMBL22648115 0.78 BRD4 (0.36) TDO2MAPTL3MBTL1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 TDO2 414/4885MAPT 4776/4885L3MBTL1 3192/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 TDO2 338/4885MAPT 4738/4885L3MBTL1 1197/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 TDO2 329/4885MAPT 4771/4885L3MBTL1 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.